Drugs / Piperacillin Sodium and Sulbactam Sodium
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01760109 | Jul 2011 → Jun 2016 | bacterial urinary tract infection, respiratory tract infectious disorder | Xiangbei Welman Pharmaceutical Co., Ltd | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Piperacillin Sodium and Sulbactam Sodium | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01760109 ↗ |
| Action | Inhibit | “the former inhibiting bacterial cell wall synthesis，the latter making irreversible competitive inhibition of β-lactamase” NCT01760109 ↗ |
| Route | Intravenous | “1.5-3.0g,iv,bid” NCT01760109 ↗ |